Clinical trials
Cystic Fibrosis trials in Poland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
43 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 4 |
| 2010 | 1 |
| 2011 | 5 |
| 2012 | 3 |
| 2014 | 2 |
| 2015 | 3 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 4 |
| 2019 | 4 |
| 2020 | 2 |
| 2021 | 2 |
| 2022 | 4 |
| 2024 | 1 |
| 2026 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 32 |
| Unknown status | 4 |
| Active, not recruiting | 3 |
| Terminated | 2 |
| Recruiting | 1 |
| Withdrawn | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Vertex Pharmaceuticals Incorporated | 10 |
| Insmed Incorporated | 4 |
| Anthera Pharmaceuticals | 3 |
| AstraZeneca | 2 |
| Chiesi Farmaceutici S.p.A. | 2 |
| Corbus Pharmaceuticals Inc. | 2 |
| Entero Therapeutics | 2 |
| Forest Laboratories | 2 |
| Gilead Sciences | 2 |
| National Institute for Tuberculosis and Lung Diseases, Poland | 2 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Cystic Fibrosis | 43 |
| Exocrine Pancreatic Insufficiency | 9 |
| Respiratory Tract Infections | 4 |
| Pseudomonas Infections | 3 |
| Eye Manifestations | 1 |
| Inflammation | 1 |
| Lipodystrophy, Congenital Generalized | 1 |
| Malabsorption Syndromes | 1 |
| Malnutrition | 1 |
| Pancreatic Diseases | 1 |
Trials
Showing 26 to 43 of 43. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.